0.6586

1.95% -0.0131

Pre-market: .63 -0.0286 -4.34%

Plus Therapeutics Inc (PSTV)

Overview News Price History Financials Discussions Forecast Stock Split

Plus Therapeutics Inc stock is traded at $0.6586, with a volume of 487.41K. It is down -1.95% in the last 24 hours and up +12.39% over the past month. Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Previous Close:

$0.6717

Open:

$0.65

24h Volume:

487.41K

Relative Volume:

0.03

Market Cap:

$10.87M

Revenue:

Net Income/Loss:

$-12.89M

P/E Ratio:

-0.2603

EPS:

-2.53

Net Cash Flow:

$-11.95M

1W Performance:

-16.33%

1M Performance:

+12.39%

6M Performance:

-53.29%

1Y Performance:

-62.69%

1-Day Range:

$0.619

$0.6607

1-Week Range:

$0.61

$0.79

52-Week Range:

$0.284

$2.6702

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name

Plus Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

737.255.7194

Address

4200 MARATHON BLVD., AUSTIN, TX

Employee

Twitter

@plustxinc

Next Earnings Date

2024-11-04

Latest SEC Filings

PSTV's Discussions on Twitter

Compare PSTV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PSTV Plus Therapeutics Inc	0.6586	10.87M	0	-12.89M	-11.95M	-2.53
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-25	Initiated	D. Boral Capital	Buy
Jan-25-21	Initiated	Ladenburg Thalmann	Buy
Oct-16-20	Initiated	Maxim Group	Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

03:51 AM

Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World

03:51 AM

Apr 19, 2025

Plus Therapeutics Appoints Kyle Guse to Board - MSN

Apr 19, 2025

Apr 15, 2025

Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada

Apr 15, 2025

Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com

Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus

Apr 15, 2025

Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus

Apr 15, 2025

Plus Therapeutics reports progress in CNS cancer treatment - Investing.com

Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire

Apr 15, 2025

New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan

Apr 15, 2025

Apr 04, 2025

Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus

Apr 04, 2025